Oragenics advances ONP-002 through Phase IIa feasibility trial in Australia
Oragenics says it is continuing to advance ONP-002, its lead intranasal mTBI candidate, through a Phase IIa feasibility trial in Australia.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.